Genetron Holdings
| General Information | |
| Business: |
We are a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. We have developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. |
| Industry: | MEDICAL LABORATORIES |
| Employees: | 697 |
| Founded: | 2015 |
| Contact Information | |
| Address | 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway Changping District, Beijing, People’s Republic of China |
| Phone Number | +86 10 5090-7500 |
| Web Address | http://www.genetronhealth.com |
| View Prospectus: | Genetron Holdings |
| Financial Information | |
| Market Cap | $1104.5mil |
| Revenues | $47.1 mil (last 12 months) |
| Net Income | $-92.7 mil (last 12 months) |
| IPO Profile | |
| Symbol | GTH |
| Exchange | NASDAQ |
| Shares (millions): | 16.0 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $256.0 mil |
| Manager / Joint Managers | Credit Suisse/ CICC |
| CO-Managers | BTIG/ Canaccord Genuity |
| Expected To Trade: | 6/19/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |